Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

IDXX

Idexx Laboratories, Inc.

May 17 • 04:00PM ET

543.45

Dollar change +2.51
Percentage change 0.46	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ IVV VO VUG IHI IWP IWF VOT

Index	NDX, S&P 500	P/E	52.66	EPS (ttm)	10.32	Insider Own	1.08%	Shs Outstand	83.03M	Perf Week	6.60%
Market Cap	44.88B	Forward P/E	43.08	EPS next Y	12.62	Insider Trans	-7.45%	Shs Float	81.69M	Perf Month	13.74%
Income	866.57M	PEG	4.39	EPS next Q	2.89	Inst Own	90.22%	Short Float	2.07%	Perf Quarter	-2.18%
Sales	3.72B	P/S	12.05	EPS this Y	10.03%	Inst Trans	-0.23%	Short Ratio	3.81	Perf Half Y	18.00%
Book/sh	18.93	P/B	28.71	EPS next Y	13.98%	ROA	28.13%	Short Interest	1.69M	Perf Year	11.56%
Cash/sh	4.81	P/C	112.93	EPS next 5Y	12.00%	ROE	71.91%	52W Range	372.50 - 583.39	Perf YTD	-2.09%
Dividend Est.	-	P/FCF	56.33	EPS past 5Y	18.76%	ROI	37.78%	52W High	-6.85%	Beta	1.35
Dividend TTM	-	Quick Ratio	1.10	Sales past 5Y	10.69%	Gross Margin	60.08%	52W Low	45.89%	ATR (14)	13.53
Dividend Ex-Date	-	Current Ratio	1.51	EPS Y/Y TTM	24.13%	Oper. Margin	29.90%	RSI (14)	65.25	Volatility	2.68% 2.65%
Employees	11000	Debt/Eq	0.68	Sales Y/Y TTM	8.57%	Profit Margin	23.26%	Recom	2.08	Target Price	581.34
Option/Short	Yes / Yes	LT Debt/Eq	0.46	EPS Q/Q	10.06%	Payout	0.00%	Rel Volume	1.00	Prev Close	540.94
Sales Surprise	-0.03%	EPS Surprise	3.60%	Sales Q/Q	7.10%	Earnings	May 01 BMO	Avg Volume	443.57K	Price	543.45
SMA20	9.49%	SMA50	5.97%	SMA200	8.53%	Trades		Volume	445,160	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral	$525
Dec-07-23	Initiated	Exane BNP Paribas	Outperform	$602
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral	$610
Jul-25-22	Downgrade	Stifel	Buy → Hold	$415
Jul-21-22	Upgrade	Goldman	Neutral → Buy	$530 → $435
Jul-12-22	Initiated	Piper Sandler	Overweight	$440
May-05-22	Downgrade	BofA Securities	Buy → Neutral	$550 → $470
Feb-08-22	Initiated	Atlantic Equities	Overweight	$650
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform	$735
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight	$600
Sep-09-19	Initiated	Goldman	Neutral	$277
May-23-19	Initiated	Guggenheim	Buy	$276
Nov-02-18	Reiterated	BofA/Merrill	Buy	$275 → $235
May-07-18	Reiterated	Stifel	Buy	$215 → $225
Jan-16-18	Initiated	Piper Jaffray	Overweight	$200
Aug-23-17	Upgrade	BofA/Merrill	Neutral → Buy
Jul-28-17	Upgrade	CL King	Neutral → Buy

Show Previous Ratings

May-14-24 02:00PM	IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day (Business Wire)
08:27AM	Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620 (MT Newswires)
May-13-24 02:25PM	Tap Into Trends: 3 Thematic ETFs to Capture the Market's Pulse (InvestorPlace)
May-04-24 07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-02-24 02:22PM	IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:17PM	Loading…
02:17PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
10:31AM	Goldman Sachs Adjusts Price Target on IDEXX Laboratories to $600 From $675 (MT Newswires)
10:30AM	BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653 (MT Newswires)
10:20AM	Stifel Adjusts Price Target on IDEXX Laboratories to $520 From $570 (MT Newswires)
09:46AM	Barclays Adjusts Price Target on IDEXX Laboratories to $570 From $655 (MT Newswires)
09:23AM	Redburn Atlantic Adjusts Price Target on IDEXX Laboratories to $500 From $460 (MT Newswires)
03:08AM	IDEXX Laboratories Inc (IDXX) (Q1 2024) Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
May-01-24 11:28PM	Q1 2024 IDEXX Laboratories Inc Earnings Call (Thomson Reuters StreetEvents) -5.02%
02:31PM	Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI (InvestorPlace)
10:41AM	IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed (Zacks)
09:30AM	Loading…
09:30AM	Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics (Zacks)
08:11AM	IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar (Reuters)
07:52AM	IDEXX Laboratories Inc (IDXX) Q1 Earnings: Exceeds Revenue Estimates, EPS Surpasses Expectations (GuruFocus.com)
07:40AM	Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates (Zacks)
07:10AM	IDEXX Laboratories' Q1 Earnings, Revenue Increase (MT Newswires)
06:38AM	Idexx: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Laboratories Announces First Quarter Results (Business Wire)
Apr-30-24 10:02AM	BofA Securities Cuts Price Target on IDEXX Laboratories to $595 From $600, Maintains Neutral Rating (MT Newswires)
Apr-28-24 06:32PM	11 Oversold Growth Stocks to Buy Right Now (Insider Monkey)
Apr-26-24 09:15AM	Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Apr-24-24 12:01PM	Eaton Vance Worldwide Health Sciences Fund Bolsters Position in IDEXX Laboratories (GuruFocus.com)
Apr-19-24 07:56AM	What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings? (Zacks)
Apr-12-24 01:53PM	New AI Bot Predicts These 7 Stocks Will Mint Millionaires (InvestorPlace)
Apr-09-24 06:00PM	Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy (Zacks)
12:10PM	Loading…
Apr-05-24 12:10PM	Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-04-24 04:30PM	IDEXX Laboratories to Release 2024 First Quarter Financial Results (Business Wire)
Apr-02-24 08:31AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Mar-29-24 02:15AM	IDEXX Laboratories (IDXX) Gained 27% on Improved Operating Margins (Insider Monkey)
Mar-21-24 05:42AM	Strong Fiscal Q3 Earnings Pushed IDEXX Laboratories (IDXX) in Q4 (Insider Monkey)
Mar-08-24 03:01AM	Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc (IDXX) (GuruFocus.com)
Mar-06-24 11:30AM	Idexx (IDXX) Down 1.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-05-24 03:05AM	Guidewire Software (GWRE) was Up 21.2% in Q4 (Insider Monkey)
Feb-22-24 03:46AM	IDEXX Laboratories (IDXX) Rebounded After Significant Drawdown From July Highs (Insider Monkey)
Feb-20-24 02:00PM	IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences (Business Wire)
Feb-18-24 01:26PM	25 Most Valuable Medical Device Companies in the US (Insider Monkey)
Feb-16-24 12:56PM	IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution (Zacks)
Feb-15-24 11:53AM	Here's Why You Should Retain IDEXX (IDXX) Stock for Now (Zacks)
07:00AM	IDEXX Launches Vello, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect (PR Newswire)
Feb-10-24 02:07AM	IDEXX Laboratories Inc Insider Sells Shares (GuruFocus.com)
Feb-09-24 03:35PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
Feb-08-24 10:34AM	IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist (Zacks)
Feb-06-24 02:25PM	IDEXX Laboratories Stock Sees RS Rating Move Higher On Earnings Beat (Investor's Business Daily)
08:46AM	IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:05AM	Q4 2023 IDEXX Laboratories Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-05-24 10:31PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research) +8.53%
10:37AM	IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall (Zacks)
09:30AM	Idexx (IDXX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:45AM	IDEXX Laboratories sees 2024 revenue above estimates (Reuters)
07:40AM	Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates (Zacks)
06:53AM	IDEXX Laboratories Inc (IDXX) Reports Solid Growth in Q4 and Full Year Earnings (GuruFocus.com)
06:39AM	Idexx: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Announces Fourth Quarter and Full Year Results (Business Wire)
Feb-02-24 08:46AM	Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings? (Zacks)
Jan-31-24 09:15AM	Unveiling Idexx (IDXX) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:29AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Jan-30-24 12:10PM	Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-29-24 11:58AM	IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store? (Zacks)
Jan-25-24 07:18AM	Here's How IDEXX Laboratories (IDXX) is Delivering Robust Financial Results (Insider Monkey)
Jan-23-24 03:30PM	IDEXX Laboratories to Release 2023 Fourth Quarter and Full Year Financial Results (Business Wire)
Jan-19-24 07:14AM	IDEXX Laboratories (IDXX) Surged in 2023 (Insider Monkey)
Jan-15-24 11:33AM	IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform (Zacks)
Jan-12-24 07:05AM	IDEXX Expands Fecal Dx Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years (PR Newswire)
07:00AM	IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx Transforming In-Clinic Workflows (PR Newswire)
Jan-11-24 09:48PM	3 Purrfect Stocks to Buy for the Booming Pet Care Industry (InvestorPlace)
Dec-18-23 07:40AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
05:19AM	Should You Add IDEXX Laboratories (IDXX) to Your Portfolio? (Insider Monkey)
Dec-09-23 01:05AM	Insider Sell: Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc (GuruFocus.com)
Dec-07-23 09:16PM	Insider Sell: President and CEO Jonathan Mazelsky Sells Shares of IDEXX Laboratories Inc (IDXX) (GuruFocus.com)
04:15PM	IDEXX Laboratories Schedules Two Institutional Investor Events (Business Wire)
Dec-06-23 03:25PM	IDEXX Laboratories Stock Earns IBD Stock Rating Upgrade (Investor's Business Daily)
Dec-04-23 08:12PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research) +7.05%
Dec-01-23 11:31AM	Idexx (IDXX) Up 11.1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-16-23 09:28AM	IDEXX Laboratories (IDXX) Declined on Weak Clinical Visits Across the Industry (Insider Monkey)
Nov-13-23 06:10AM	IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis (Zacks)
Nov-11-23 12:00PM	IDEXX Laboratories (IDXX) Fell on Investors Concerns (Insider Monkey)
Nov-09-23 07:48AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Nov-08-23 07:00AM	IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases (PR Newswire)
Nov-02-23 06:55PM	IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.09%
08:52AM	Zoetis cuts annual sales forecast as inflation weights on pet spending (Reuters)
01:10AM	The IDEXX Laboratories Inc (IDXX) Company: A Short SWOT Analysis (GuruFocus.com)
12:45AM	Q3 2023 IDEXX Laboratories Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 10:00PM	Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics (Zacks)
02:52PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
09:53AM	IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down (Zacks)
09:28AM	IDEXX Laboratories Inc (IDXX) Reports 9% Revenue Growth in Q3 2023 (GuruFocus.com)
08:46AM	IDEXX cuts annual sales forecast as pet owners remain cautious on vet visits (Reuters)
06:40AM	Idexx: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Laboratories Announces Third Quarter Results (Business Wire)
Oct-31-23 11:25AM	MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More (Zacks)
Oct-25-23 10:02AM	Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-23 06:19AM	IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store? (Zacks)
Oct-13-23 11:40AM	IART vs. IDXX: Which Stock Is the Better Value Option? (Zacks)
Oct-06-23 07:30AM	T2 Biosystems (TTOO) vs. IDEXX Laboratories (IDXX): Which Medical Stock Is Poised for More October Gains? (Entrepreneur: Stocks)
Oct-05-23 04:00PM	IDEXX Laboratories to Release 2023 Third Quarter Financial Results (Business Wire)

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kingsley Lawrence D	Director	May 06 '24	Option Exercise	0.00	339	0	8,883	May 08 07:02 PM
SZOSTAK M ANNE	Director	May 06 '24	Option Exercise	0.00	257	0	257	May 08 07:02 PM
Vandebroek Sophie V.	Director	May 06 '24	Option Exercise	0.00	257	0	1,473	May 08 07:02 PM
COLLINS Asha	Director	May 06 '24	Option Exercise	0.00	257	0	779	May 08 07:01 PM
ESSIG STUART	Director	May 06 '24	Option Exercise	0.00	257	0	1,974	May 08 07:01 PM
AYERS JONATHAN W	Director	May 06 '24	Option Exercise	0.00	257	0	265,651	May 08 07:00 PM
Britt Irene Chang	Director	May 06 '24	Option Exercise	0.00	208	0	208	May 08 07:00 PM
POLEWACZYK JAMES F	Executive Vice President	Mar 06 '24	Option Exercise	422.45	8,104	3,423,547	18,815	Mar 07 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Mar 06 '24	Sale	558.44	8,104	4,525,596	10,711	Mar 07 05:00 PM
Vandebroek Sophie V.	Director	Mar 05 '24	Option Exercise	245.79	1,404	345,089	2,620	Mar 07 05:00 PM
Vandebroek Sophie V.	Director	Mar 05 '24	Sale	562.98	1,404	790,427	1,216	Mar 07 05:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 21 '24	Option Exercise	206.94	483	99,952	82,047	Feb 22 05:02 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	Feb 16 '24	Option Exercise	206.94	483	99,952	5,595	Feb 20 05:01 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 15 '24	Option Exercise	206.94	483	99,952	30,835	Feb 20 05:00 PM
Smith Martin Alexander	Executive Vice President	Feb 14 '24	Option Exercise	0.00	337	0	583	Feb 16 05:58 PM
Schreck Michael	Executive Vice President	Feb 14 '24	Option Exercise	0.00	368	0	903	Feb 16 05:58 PM
Johnson Michael Perkins	EVP and CHRO	Feb 14 '24	Option Exercise	0.00	176	0	243	Feb 16 05:56 PM
Lane Michael	Executive Vice President	Feb 14 '24	Option Exercise	0.00	939	0	6,726	Feb 16 05:56 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 14 '24	Option Exercise	0.00	4,156	0	83,403	Feb 16 05:56 PM
Erickson Michael G	Executive Vice President	Feb 14 '24	Option Exercise	0.00	462	0	10,801	Feb 16 05:54 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 14 '24	Option Exercise	0.00	370	0	7,082	Feb 16 05:55 PM
Hunt Nimrata	Executive Vice President	Feb 14 '24	Option Exercise	0.00	664	0	11,731	Feb 16 05:55 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 14 '24	Option Exercise	0.00	1,731	0	31,449	Feb 16 05:57 PM
POLEWACZYK JAMES F	Executive Vice President	Feb 14 '24	Option Exercise	0.00	927	0	10,990	Feb 16 05:57 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 08 '24	Option Exercise	62.00	9,810	608,220	14,910	Feb 09 05:03 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 08 '24	Sale	573.87	8,198	4,704,559	6,712	Feb 09 05:03 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 07 '24	Option Exercise	141.60	23,326	3,302,962	53,044	Feb 09 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 07 '24	Option Exercise	67.85	12,000	814,200	91,247	Feb 09 05:00 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 07 '24	Sale	570.01	23,326	13,295,975	29,718	Feb 09 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 07 '24	Sale	572.61	12,000	6,871,319	79,247	Feb 09 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Dec 07 '23	Option Exercise	253.92	11,636	2,954,645	21,686	Dec 08 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Dec 07 '23	Sale	521.79	11,636	6,071,500	10,050	Dec 08 05:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Dec 04 '23	Option Exercise	79.54	13,424	1,067,745	86,361	Dec 06 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Dec 04 '23	Sale	513.05	7,128	3,657,049	79,233	Dec 06 05:01 PM
Lane Michael	Executive Vice President	Nov 07 '23	Option Exercise	133.76	1,728	231,142	5,774	Nov 08 05:09 PM
Smith Martin Alexander	Executive Vice President	Sep 01 '23	Option Exercise	0.00	19	0	226	Sep 06 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 31 '23	Option Exercise	79.54	13,424	1,067,745	86,349	Sep 05 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 31 '23	Sale	512.01	13,424	6,873,267	72,925	Sep 05 05:01 PM
POLEWACZYK JAMES F	Executive Vice President	Aug 29 '23	Option Exercise	144.21	16,909	2,438,478	32,947	Aug 31 05:17 PM
POLEWACZYK JAMES F	Executive Vice President	Aug 29 '23	Sale	510.56	22,909	11,696,446	10,038	Aug 31 05:17 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 05 '23	Option Exercise	0.00	384	0	73,095	Aug 08 05:59 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Aug 05 '23	Option Exercise	0.00	192	0	29,809	Aug 08 05:59 PM
Lane Michael	Executive Vice President	Aug 03 '23	Option Exercise	187.47	16,027	3,004,598	20,061	Aug 07 05:04 PM
Lane Michael	Executive Vice President	Aug 03 '23	Sale	510.00	16,027	8,173,770	4,034	Aug 07 05:04 PM

Dollar change -0.31
Percentage change -1.27	%

Held by: IJR VTI CALF VB IWM VXF VBK FBT IWO IBB

Index	RUT	P/E	9.52	EPS (ttm)	2.54	Insider Own	1.45%	Shs Outstand	166.98M	Perf Week	0.42%
Market Cap	4.09B	Forward P/E	9.27	EPS next Y	2.61	Insider Trans	-0.63%	Shs Float	166.77M	Perf Month	1.64%
Income	434.43M	PEG	0.38	EPS next Q	0.67	Inst Own	105.34%	Short Float	7.73%	Perf Quarter	-24.95%
Sales	1.73B	P/S	2.37	EPS this Y	90.93%	Inst Trans	-1.26%	Short Ratio	6.68	Perf Half Y	9.57%
Book/sh	7.42	P/B	3.26	EPS next Y	-5.21%	ROA	23.94%	Short Interest	12.89M	Perf Year	-16.20%
Cash/sh	4.40	P/C	5.49	EPS next 5Y	24.80%	ROE	42.85%	52W Range	20.46 - 32.88	Perf YTD	-12.94%
Dividend Est.	-	P/FCF	10.37	EPS past 5Y	-	ROI	26.88%	52W High	-26.55%	Beta	0.49
Dividend TTM	-	Quick Ratio	2.77	Sales past 5Y	10.61%	Gross Margin	83.32%	52W Low	18.03%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	3.20	EPS Y/Y TTM	361.04%	Oper. Margin	22.07%	RSI (14)	43.68	Volatility	3.04% 2.59%
Employees	2100	Debt/Eq	0.29	Sales Y/Y TTM	54.01%	Profit Margin	25.17%	Recom	2.15	Target Price	34.25
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	183.98%	Payout	0.00%	Rel Volume	0.75	Prev Close	24.46
Sales Surprise	-2.74%	EPS Surprise	-26.21%	Sales Q/Q	21.83%	Earnings	May 01 BMO	Avg Volume	1.93M	Price	24.15
SMA20	-0.66%	SMA50	-6.40%	SMA200	-8.43%	Trades		Volume	1,444,956	Change	-1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24
Jul-30-20	Downgrade	Goldman	Neutral → Sell	$19 → $15
Feb-14-20	Reiterated	H.C. Wainwright	Neutral	$26 → $25
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral	$21
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral	$31 → $20
Feb-06-20	Initiated	Mizuho	Neutral

Show Previous Ratings

May-15-24 12:14PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
May-14-24 07:00AM	Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences (PR Newswire)
May-02-24 11:39AM	Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
11:15AM	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating (MT Newswires)
07:00AM	Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
11:54AM	Loading…
May-01-24 11:54AM	ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:07AM	Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:36AM	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View (MT Newswires)
09:30AM	Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:30AM	Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates (Zacks)
07:26AM	Alkermes: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 08:00AM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? (Investor's Business Daily)
Apr-24-24 07:00AM	Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 (PR Newswire)
Apr-22-24 02:14PM	Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? (Zacks)
04:00PM	Loading…
Apr-17-24 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-11-24 10:15AM	Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study (Zacks)
10:00AM	Alkermes' Innovations Are Transforming Mental Health Treatments (GuruFocus.com)
Apr-10-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Apr-09-24 12:38PM	BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 (Associated Press Finance)
07:00AM	Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia (PR Newswire)
Apr-08-24 07:00AM	Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society (PR Newswire)
Apr-02-24 12:10PM	Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again (Zacks)
Mar-18-24 07:01PM	Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS) (GuruFocus.com)
Mar-15-24 06:15PM	Alkermes (ALKS) Stock Moves -0.45%: What You Should Know (Zacks)
Mar-13-24 12:45PM	3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock (Zacks)
Mar-12-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-08-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
06:15PM	Loading…
Mar-07-24 06:15PM	Why Alkermes (ALKS) Outpaced the Stock Market Today (Zacks)
07:00AM	Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors (PR Newswire)
Feb-29-24 06:15PM	Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Feb-23-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Feb-21-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Feb-16-24 10:18AM	Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 02:40PM	Alkermes Stock Gets RS Rating Upgrade; Profits Surge (Investor's Business Daily) +16.33%
01:34PM	Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates (Zacks)
09:30AM	Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics (Zacks)
07:37AM	Alkermes PLC (ALKS) Reports Strong 2023 Financial Results and Sets Positive Outlook for 2024 (GuruFocus.com)
07:30AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 (PR Newswire)
Feb-12-24 09:16AM	Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-08-24 04:10PM	7 Biotech Stocks Fighting Americas Deadliest Diseases (InvestorPlace)
04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 (PR Newswire)
10:00AM	Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-07-24 06:15PM	Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Feb-02-24 02:15AM	The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 (InvestorPlace)
Feb-01-24 06:15PM	Alkermes (ALKS) Stock Dips While Market Gains: Key Facts (Zacks)
05:00PM	3 Top Pharma Stocks to Buy Now: February 2024 (InvestorPlace)
Jan-30-24 12:10PM	Why Alkermes (ALKS) Could Beat Earnings Estimates Again (Zacks)
Jan-26-24 06:15PM	Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
Jan-12-24 06:15PM	Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jan-03-24 04:00PM	Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
07:00AM	Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan) (PR Newswire)
Dec-27-23 11:45AM	Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes (ACCESSWIRE)
Dec-22-23 06:15PM	Alkermes (ALKS) Outperforms Broader Market: What You Need to Know (Zacks)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
12:15PM	Corporate Governance at Alkermes (ACCESSWIRE)
Dec-18-23 01:45PM	Alkermes' Commitment to Integrity and Compliance (ACCESSWIRE)
Dec-14-23 10:45AM	Alkermes' Culture of Employee Engagement and Wellness (ACCESSWIRE)
06:05AM	Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
Dec-13-23 04:08AM	12 Best Growth Stocks to Buy According to Billionaire Ray Dalios Bridgewater Associates (Insider Monkey)
Dec-11-23 02:30PM	Patient Advocacy and Community Engagement at Alkermes (ACCESSWIRE)
Dec-01-23 06:16PM	Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-29-23 03:15PM	Pharmaceuticals in the Environment (ACCESSWIRE)
Nov-24-23 11:31AM	Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report? (Zacks)
Nov-21-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
11:45AM	Environmental Protection & Sustainability at Alkermes (ACCESSWIRE)
Nov-20-23 01:45PM	Alkermes Celebrates #Movember for Mens Health Awareness Month (ACCESSWIRE)
Nov-16-23 10:30AM	Alkermes' Waste Optimization Highlights (ACCESSWIRE) +6.03%
Nov-15-23 08:57AM	Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout (FierceBiotech.com)
07:15AM	Alkermes separates cancer drug business as new company Mural (BioPharma Dive)
07:00AM	Alkermes Completes Separation of Oncology Business (PR Newswire)
Nov-14-23 01:45PM	Our Commitment to Caregivers (ACCESSWIRE)
10:33AM	Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition (Zacks)
05:50AM	3 Growth Stocks Set to Dominate the Decade (InvestorPlace)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
12:45PM	Product Stewardship and Environmental Impact at Alkermes (ACCESSWIRE)
Nov-10-23 03:00PM	Caring for Caregivers: Alkermes Celebrates National Caregivers Month (ACCESSWIRE)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
Nov-08-23 11:30AM	Environmental Health and Safety at Alkermes (ACCESSWIRE)
Nov-07-23 04:00PM	Alkermes to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-31-23 05:08PM	Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement (PR Newswire)
01:30PM	Operating and Growing Responsibly at Alkermes (ACCESSWIRE)
Oct-26-23 12:00PM	Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat (Zacks) +5.33%
10:37AM	Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-25-23 12:38PM	Why Alkermes Stock Is Sinking Today (Motley Fool) -7.39%
09:30AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:23AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly)
Oct-23-23 04:00PM	Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. (Investor's Business Daily) -9.59%
02:00PM	Alkermes CEO Reflects on Living Company Purpose (ACCESSWIRE)
08:00AM	Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress (PR Newswire)
Oct-19-23 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-23 06:15PM	Alkermes (ALKS) Dips More Than Broader Market: What You Should Know (Zacks)
04:00PM	Alkermes to Report Third Quarter Financial Results on October 25, 2023 (PR Newswire)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 18 '24	Sale	28.10	10,417	292,740	65,911	Mar 18 04:02 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 27 '24	Sale	29.65	2,559	75,874	7,717	Feb 27 04:09 PM
LAURENCIN CATO T	Director	Feb 15 '24	Option Exercise	22.52	2,690	60,579	17,859	Feb 16 04:01 PM
LAURENCIN CATO T	Director	Feb 15 '24	Sale	31.85	2,690	85,676	15,169	Feb 16 04:01 PM
LAURENCIN CATO T	Director	Jun 08 '23	Option Exercise	22.97	2,638	60,595	10,117	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 08 '23	Sale	31.85	2,638	84,020	7,479	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 07 '23	Option Exercise	22.97	2,800	64,316	10,279	Jun 07 05:12 PM
LAURENCIN CATO T	Director	Jun 07 '23	Sale	31.50	2,800	88,200	7,479	Jun 07 05:12 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30 '23	Option Exercise	20.43	19,634	401,123	68,118	May 30 08:16 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30 '23	Sale	28.93	27,134	784,862	40,984	May 30 08:16 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

IDXX

Idexx Laboratories, Inc.

ALKS

Alkermes plc

Upgrade your FINVIZ experience